



**Professor Michael P. Manns, M.D.**  
President of Hannover Medical School (MHH)

Hannover Medical School (MHH)  
Carl-Neuberg-Straße 1 · 30625 Hannover/Germany

+49 511 532-6000 / 6001

+49 511 532-6003

manns.michael@mh-hannover.de

www.mhh.de

**CURRICULUM VITAE**

1970–1976	Medical School, University of Vienna, Austria, and Johannes-Gutenberg-University, Mainz, Germany	1999–2001	Member, Senate of MHH
1976	Doctor of Medicine	2009–2011	Member, Senate of MHH
1977	Licence as MD	2013–2018	Member, Senate of MHH
1977–1981	Resident and Fellow, Department of Internal Medicine, Klinikum Charlottenburg, Freie Universität Berlin, Germany	since 2002	Founder and Chairman of Hep-Net, national network of competence on viral hepatitis
1981–1985	Resident and Fellow, Department of Medicine I, University of Mainz, Germany	2003–2006	Commission of the senate of the German Research Foundation „DFG“ for Sonderforschungsbereiche (SFBs)
1984	Licence for Internal Medicine	2004–2010	Founder and chair DFG Clinical Research Group on Hepatocellular Carcinoma (KFO 119)
1985	Subspecialist for Gastroenterology and Hepatology	2004–2013	Member, Board of Supervisors, University Hospital Magdeburg
1985–1991	Staff Physician (Oberarzt), Department of Medicine I, University of Mainz, Germany	2005–2009	Chairman, Center of Internal Medicine, Hannover Medical School (MHH)
1986	Professor of Medicine and Gastroenterology, University of Mainz	2005–2009	Steering committee member of VIRGIL, EU network of excellence on viral resistance in flue and viral hepatitis
1987–1988	Research Associate – W.M. Keck Autoimmune Disease Centre, Scripps Clinic and Research Foundation, Dept. of Basic and Clinical Research, La Jolla, CA, USA	since 2006	Founder and President, German Liver Foundation
1991–2020	Chairman, Department of Gastroenterology, Hepatology and Endocrinology, Center of Internal Medicine, Hannover Medical School (MHH)	2006	President, German Society of Gastroenterology (DGVS)
1997–1999	Medical Director, MHH	2006–2018	Member, Steering Committee of REBIRTH, DFG Cluster of Excellence on Regenerative Medicine
1997–2003	Chairman, Sonderforschungsbereich 265 (collaborative project) of DFG “Pathophysiology and Immune Reactions after Organ Transplantation”	2007–2019	Chairman, Sonderforschungsbereich 738 (collaborative project) of DFG “Optimizing conventional and innovative transplants”
1998–2020	Member, Scientific Advisory Board, Robert Koch Institute, Berlin	2008–2018	Member, Steering Committee of BMBF-IFB, integrated center for research and treatment in transplantation medicine
1998–2013	Member, Board of Supervisors, University Hospital Erlangen, Germany	since 2009	Member, Board of Supervisors, University Hospital Mainz, Germany

2010–2014	Vice Chairman, Transregio - SFB 77, "Liver Cancer"
2010	Member, commission for structures in academic medicine (MSK), Baden- Württemberg, Stuttgart
2011–2018	Coordinator, Translational Thematic Unit Hepatitis, German Center for Infection Research (DZIF)
2011–2019	Member, selection committee, Alexander von Humboldt Foundation, Bonn, Germany
since 2011	Member, External Scientific Council, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Spain
2011–2015	Member, European BioMedAlliance, Brussels
2013–2023	Board Member, Boehringer Ingelheim Foundation
2015–2020	Member, Scientific Panel for Health (SPH), European Commission, Brussels
2015–2018	Clinical Director, Helmholtz Centre for Infection Research (HZI), Braunschweig
2015–2018	Founding Director, Centre for Individualised Infection Medicine (CiiM), Hannover
2016–2020	Member, Board of Trustees of the University of Lübeck
since 2017	Vice Chairman, Transregio-SFB 209 „Liver Cancer – New mechanistic and therapeutic concepts in a solid tumor model“
since 2019	President, Hannover Medical School (MHH), Germany

## ACTIVITIES IN THE SCIENTIFIC COMMUNITY, HONORS, AWARDS

1985	Boehringer Ingelheim Award, University of Mainz, Germany
1990	NATO Collaboration Research Award, Brussels, Belgium
1990	Clinical Research Award, GSK Foundation, Göttingen
1991	Clemens van Pirquet Award, University of California Davis, USA
1991	Ralph Wright Memorial Lecture, British Association for the Study of the Liver, London, UK
1993	Sheila Sherlock State of the Art Lecture, Int. Association for the Study of the Liver, Cancun, Mexico
1995	International Hans Popper Award Basel, Switzerland
1997	Sir Michael Perrin Lecture, Royal College of Physicians, London, UK
1996–2007	Ordinary member of the ‚Arzneimittelkommission der deutschen Ärzteschaft‘

2000	Leon Schiff State-of-the-Art Lecture, American Association for the Study of the Liver, Dallas, USA
2002	Dr. Robert-Pfleger-Award, Bamberg, Germany
since 2002	Member, Leopoldina, National Academy of Science, Halle, Germany
2003	Max-Siurala-Award, Finish Society of Gastroenterology, Turku, Finland
since 2004	Member, Göttingen Academy of Sciences and Humanities in Lower Saxony, Germany
since 2005	Honorary Member, Argentinian Association for the Study of the Liver
2006	President, German Society of Gastroenterology (DGVS)
since 2006	Honorary Member, Hungarian Society of Gastroenterology
2006	Corriere della Sera, Milano: MHH Department of Gastroenterology, Hepatology and Endocrinology is leading centre for liver research in Europe
2007	EASL Recognition Award, Barcelona, Spain
2008	Sheila Sherlock State-of-the-Art Lecture, British Society of Gastroenterology, Birmingham, UK
2008	Most cited European author in Gastroenterology and Hepatology (1996 – 2006) ( <a href="http://www.lab-times.org">www.lab-times.org</a> )
2009	Hippokrates Award, Hellenic Society of Internal Medicine, Athens
2010	Resnick Lecturer and Visiting Professor, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
2011	Ulrika Broome Lecture, Swedish Society of Gastroenterology, Umea, Sweden
2011	Sherbaniuk-Wensel Lectureship, University of Alberta, Edmonton, Canada
2012	Corresponding member, Academy of Science and Literature Mainz, Germany
2012	Int. Hans Popper Lecturer, Medical University of Vienna, Vienna, Austria
2013	President, German Ass. for the Study of the Liver (GASL)
2013–2014	President, German Society of Internal Medicine (DGIM)
since 2014	Highly Cited Researcher by Clarivate (Web-of-Science), formerly Thomson Reuters, Top 1% most cited researcher
2015	Sheila Sherlock Lecturer, Toronto University, Toronto, Canada
2015	Tzu-Leung Ho Lecturer, International Digestive Disease Forum, Hong Kong

2015	Roy Calne-Roger Williams Lecture of the British Association for the Study of the Liver (BASL), London, UK
2015–2022	Associate Editor, Clinical Gastroenterology and Hepatology
2016–2017	President, United European Gastroenterology (UEG)
2016	Ring of Honor, City of Garbsen, Garbsen, Germany
2019	Honorary Member, Austrian Society of Gastroenterology and Hepatology, (ÖGGH)
since 2018	Co-Chair- EASL-Lancet-Liver-Commission
2021	Honorary Member, German Society of Gastroenterology (DGVS)
2022	Honorary Member, German Society of Internal Medicine (DGIM)
2022	Life Time Achievement Award, United European Gastroenterology (UEG)
2022	Walter-Siegenthaler-Medal in Gold, Walter-Siegenthaler-Society, Cologne
2023	Honorary Fellow of the Royal College of Physicians of Thailand (RCPT), Bangkok, Thailand
2023	Honorary Member of the Society of Gastroenterology in North Rhine-Westphalia (NRW) e.V., Essen

## RESEARCH FIELDS

- » inflammatory liver diseases, viral and autoimmune
- » clinical trials for the treatment of liver diseases, in particular viral hepatitis, autoimmune liver diseases, liver transplantation
- » transplantation medicine   » gastrointestinal oncology, in particular hepatocellular carcinoma
- » regenerative medicine       » clinical pharmacology

## SELECTED PUBLICATIONS

**Manns MP**, Meyer zum Bueschenfelde KH. A mitochondrial antigen-antibody system in cholestatic liver disease detected by radioimmunoassay. *Hepatology* 2: 1-7 (1982).

**Manns MP**, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Bueschenfelde KH. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. *The Lancet* 1: 292-294 (1987).

**Manns MP**, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. The major antigen of liver-kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450 db1. *J Clin Invest* 83: 1066-1079 (1989).

**Manns MP**, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P4502D6, a cytochrome P450 monooxygenase. *J Clin Invest* 88(4): 1370-1378 (1991).

Michel G, Ritter A, Gerken G, Meyer zum Bueschenfelde KH, Decker R, **Manns MP**. Anti- GOR and hepatitis C virus in autoimmune liver diseases. *The Lancet* 339: 267-9 (1992).

Philipp T, Durazzo M, Trautwein C, Alex B, Straub P, Lamb G, Johnson EF, Tukey RH, **Manns MP**. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. *The Lancet* 344: 578-581 (1994).

Desmet V, Gerber MA, Hoofnagle JH, **Manns MP**, Scheuer P. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology* 19: 1513-20 (1994).

Takaki, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, **Manns MP**, Rehermann B. Cellular immune responses persist, humoral responses decline two decades after recovery from a single source outbreak of hepatitis C. *Nat Med* 6: 578-582 (2000).

Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, **Manns MP**. German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med* 15;345: 1452-1457 (2001).

**Manns MP**, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *The Lancet*. 358: 958-65 (2001).

Tillmann HL, Heiken H, Knapik-Botor A, Heringlake S, Ockenga J, Wilber JC, Georgen B, Detmer J, McMorrow M, Stoll M, Schmidt RE, **Manns MP**. Infection with GB virus C and reduced mortality among HIV-infected patients. *N Engl J Med* 345: 715-724 (2001).

Zender L, Hütker S, Liedke C, Tillmann HL, Zender S, Mundt B, Waltemathe M, Gösling T, Flemming P, Malek NP, Trautwein C, **Manns MP**, Kühnel F, Kubicka S. Caspase 8 siRNA prevents acute liver failure in mice. *Proc Natl Acad Sci USA* 100: 7797-802 (2003).

Kossatz U, Vervoorts J, Nickeleit I, Sundberg HA, Arthur JS, **Manns MP**, Malek NP. C-terminal phosphorylation controls the stability and function of p27kip1. *EMBO J* 25: 5159-5170 (2006).

Timmerbeul I, Garrett-Engele CM, Kossatz U, Chen X, Firpo E, Grünwald V, Kamino K, Wilkens L, Lehmann U, Buer J, Geffers R, Kubicka S, **Manns MP**, Porter PL, Roberts JM, Malek NP. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. *Proc Natl Acad Sci USA* 103: 14009-14014 (2006).

**Manns MP**, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment—finding the right path. *Nat Rev Drug Discov* 6(12): 991-1000 (2007).

Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, Johnson EF, Gonzalez FJ, Pfeilschifter J, **Manns MP**, Herrath MG, Christen U. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. *J Exp Med* 205: 1409-22 (2008).

Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, **Manns M**, K otzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *N Engl J Med* 359: 2442-55 (2008).

**Manns MP**, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. AASLD Practice Guidelines: Diagnosis and Management of Autoimmune Hepatitis. *Hepatology* 51: 2193-2213 (2010).

McHutchison JG, **Manns MP**, Muir AJ, Terrault NA, Jacobson IM, Afdahl NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, DiBisceglie AM and the PROVE 3 Study Team. Telaprevir combined with Peginterferon and ribavirin in hepatitis C patients who have not had a sustained virologic response to initial interferonbased therapy. *N Engl J Med* 362: 1292 – 303 (2010).

**Manns MP**, Woynarkowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, Bahr MJ, Gunther R, Hultcrantz RW, Spengler U, Lohse AW, Szalay F, Farkkila M, Proels M, Strassburg CP. Azathioprine with budesonide induces remission more effectively than with prednisone in patients with autoimmune hepatitis. *Gastroenterology* 139: 1198-1206 (2010).

Lankisch TO, Metzger J, Negm AA, Vosskuhl K, Schiffer E, Siwy J, Weismüller TJ, Schneider AS, Thediack K, Baumeister R, Zürgb P, Weissinger EM, **Manns MP**, Mischak H, Wedemeyer J. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. *Hepatology*; 53:875-84 (2011).

Wedemeyer H, Yurdaydin C, Dalekos G, Ehrhardt A, Cakaloglu Y, Degertekin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Bock CT, Dienes H, **Manns MP**. Peginterferon plus Adefovir versus either drug alone for hepatitis delta. *New Engl J Med* 364: 322 – 331 (2011).

Poordad F, McCone J Jr, Bacon BR, Bruno S, **Manns MP**, Sulkowski MS, Jacobson IM, Reddy KR, Goodman Z, Boprai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. *New Engl J Med*, 364: 1195-206 (2011).

Kang TW, Yevsa T, Woller N, Hoenecke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, **Manns M**, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, Zender L. Senescence surveillance of premalignant hepatocytes limits liver cancer development. *Nature*, 479: 547– 551 (2011).

Zender S, Nicleleit I, Wuestefeld T, Sörensen I, Dauch D, Bozko P, El-Khatib M, Geffers R, Bektas H, **Manns MP**, Gossler A, Wilkens L, Plentz R, Zender L, Malek NP. A critical role for notch signaling in the formation of cholangiocellular carcinomas. *Cancer Cell* 23: 784-95 (2013)

Wuestefeld T, Pesic M, Rudalska R, Dauch D, Longerich T, Kang TW, Yevsa T, Heinzmann F, Hoenicke L, Hohmeyer A, Potapova A, Rittmeier I, Jarek M, Geffers R, Scharfe M, Klawonn F, Schirmacher P, Malek NP, Ott M, Nordheim A, Vogel A, **Manns MP**, Zender L. A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. *Cell* 153: 389-401 (2013).

Woynarowski M, Nemeth A, Baruch Y, Koletzko S, Melter M, Rodeck B, Strassburg C, Pröls M, Wozniak M, **Manns MP**, European Autoimmune Hepatitis-Budesonide Study Group. Budesonide versus Prednisone with Azathioprine for the Treatment of Autoimmune Hepatitis in Children and Adolescents. *The Journal of Pediatrics* 163: 1347-53 (2013).

Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Großhennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlapphoff V, Cornberg M, **Manns MP**, Wedemeyer H; Hep-Net Acute HCV-III Study Group. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled noninferiority trial. *Lancet Infect Dis.* 13: 497-506 (2013).

**Manns MP**, von Hahn T. Novel therapies for hepatitis C - one pill fits all? *Nat Rev Drug Discovery* 12: 595-610 (2013).

**Manns M**, Marcellin P, Poordad F, Affonso de Araujo S A, Buti M, Horsmans Y, Janczewska W, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, de la Rosa G, Kalmeijer R, Sinha R, Beumont-Maiviel M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis c virus genotype 1 infection (QUEST-2): a randomized, double-blind, placebo-controlled phase 3 trial. *The Lancet* 384: 414-426 (2014).

**Manns M**, Pol S, Jacobsen IM, Marcellin P, Gordon SC, Peng C-H, Chang T-T, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu C-J, Sievert W, Bronowicki J-P, Thabut D, Lee Y-J, Kao J-H, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S, on behalf of the HALLMARK-DUAL Study Team: All oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. *The Lancet* 384: 1597-1605 (2014).

Charlton M, Gane E, **Manns MP**, Brown RS Jr, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, McHutchison JG, Symonds WT, Brainard D, Kirby B, Dvory-Sobol H, Denning J, Arterburn S, Samuel D, Forns X, Terrault NA. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. *Gastroenterology* 148: 108-17 (2015).

Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, **Manns MP**. Extrahepatic Morbidity and mortality of chronic hepatitis C. *Gastroenterology* 149: 1345-1360 (2015).

**Manns M**, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterbum S, Pang PS, Brainard D, McHutchison JG, Dufour F, Van Vlierberghe H, van Hoek B, Forns X for the SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. *Lancet Infect Dis* 16: 685-97 (2016).

Yang D, Yuan Q, Balakrishnan A, Bantel H, Klusmann JH, **Manns MP**, Ott M, Cantz T, Sharma AD. MicroRNA-125b-5p mimic inhibits acute liver failure. *Nat Commun* 7:11916 (2016).

**Manns MP**, Buti M, Gane EJ, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Nature Reviews Disease Primers - Hepatitis C virus infection. *Nat Rev Dis Primers*. 3, 17006 (2017).

Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, Spengler U, Wiegand J, Schulze Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner C, Zeuzem S, Papkalla A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorf D, **Manns MP**, Wedemeyer H; HepNet Acute HCV IV Study Group, Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 mono-infection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. *Lancet Infect Dis*; 17:215-22 (2017).

Bourlière M, Bourlière M1, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, **Manns MP**, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. *N Engl J Med* 2017 376(22):2134-2146 (2017).

Strunz B, Hengst J, Deterding K, **Manns MP**, Cornberg M, Ljunggren HG, Wedemeyer H, Björkström NK; Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. *Nat Commun*. 2018 9(1):2275 (2018).

**Manns MP**, Burra P, Sargent J, Horton R, Karlsen TH; The Lancet-EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities. *Lancet*. 2018 392(10148):621-622 (2018)

Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, **Manns MP**; HIDIT-II study team; Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. *Lancet Infect Dis* 2019 19(3):275-286 (2019).

Niemann J, Woller N, Brooks J, Fleischmann- Mundt B, Martin NT, Kloos A, Knocke S, Ernst AM, **Manns MP**, Kubicka S, Wirth TC, Gerardy-Schahn R, Kühnel F; Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy. *Nat Commun*. 2019 10 (1):3236 (2019).

Mack CL, Adams D, Assis DN, Kerkar N, **Manns MP**, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ; Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases. *Hepatology* 2020 Aug;72(2):671-722. Epub ahead of print (2019).

Goeppert B, Folseraas T, Roessler S, Kloor M, Volckmar AL, Endris V, Buchhalter I, Stenzinger A, Grzyb K, Grimsrud MM, Gornicka B, von Seth E, Reynolds GM, Franke A, Gotthardt DN, Mehrabi A, Cheung A, Verheij J, Arola J, Mäkisalo H, Eide TJ, Weidemann S, Chevillat JC, Mazza G, Hirschfield GM, Ponsioen CY, Bergquist A, Milkiewicz P, Lazaridis KN, Schramm C, **Manns MP**, Färkkilä M, Vogel A; International PSC study group, Boberg KM, Schirmacher P, Karlsen TH; Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities. *Hepatology* 2020;72(4):1253-1266. Epub ahead of print (2020).

Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Jarvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Gines P, Buti M, Newsome PN, Burra P, **Manns MP**. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. *Lancet* 2022 Jan 1;399(10319):61-116.

*More than 1.000 publications,  
Hirsch Index of > 140 (Web-of-Science, April, 2024)*